Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Dipartimento per le Scienze della salute della donna, del bambino e di Sanità Pubblica, Roma, Italia; Università Cattolica del Sacro Cuore, Roma, Italia.
Mater Olbia Hospital, Olbia, Italia.
Fertil Steril. 2022 Jan;117(1):160-168. doi: 10.1016/j.fertnstert.2021.08.032. Epub 2021 Oct 14.
To characterize T lymphocyte infiltration and programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) expression in early-stage endometriosis-associated ovarian cancer (EAOC), ovarian endometriosis (OE), atypical endometriosis (AE), and deep endometriosis (DE).
Case-control, retrospective study.
Research University Hospital.
PATIENT(S): A total of 362 patients with a histologic diagnosis of EAOC, OE, AE, or DE were identified between 2000 and 2019 from Fondazione Policlinico Universitario Agostino Gemelli IRCCS and Gemelli Molise SpA tissue data banks. A 1:1 propensity score-matched method yielded matched pairs of 55 subjects with EAOC, 55 patients with OE, 12 patients with AE, and 42 patients with DE, resulting in no differences in family history of cancer, parity, and use of oral contraceptives.
INTERVENTION(S): Immunohistochemistry assays using the following primary antibodies: CD3+; CD4+; CD8+; PD-1; and PD-L1.
MAIN OUTCOME MEASURE(S): To characterize T lymphocyte infiltration and PD-1/PD-L1 expression in 4 different endometriosis-related diseases.
RESULT(S): Endometriosis-associated ovarian cancer cases displayed significantly higher levels of PD-1/PD-L1 expression compared with all other endometriosis-related diseases (vs. OE vs. AE vs. DE). Moreover, a significantly lower count of infiltrating T lymphocytes was observed in EAOC cases compared with OE ones. Finally, one-third of OE cases showed a cancer-like PD-1/PD-L1 expression profile.
CONCLUSION(S): Endometriosis-associated ovarian cancer is characterized by higher levels of PD-1/PD-L1 expression compared with benign endometriosis-related diseases. This profile was found in one-third of clinically benign cases, suggesting that it develops early in the carcinogenesis process.
描述早期子宫内膜异位症相关卵巢癌（EAOC）、卵巢子宫内膜异位症（OE）、不典型子宫内膜异位症（AE）和深部子宫内膜异位症（DE）中 T 淋巴细胞浸润和程序性死亡蛋白 1（PD-1）/程序性死亡配体 1（PD-L1）的表达特征。
病例对照、回顾性研究。
研究型大学医院。
2000 年至 2019 年期间，从 Fondazione Policlinico Universitario Agostino Gemelli IRCCS 和 Gemelli Molise SpA 组织数据库中确定了 362 例组织学诊断为 EAOC、OE、AE 或 DE 的患者。采用 1:1 倾向评分匹配法获得了 55 例 EAOC 患者、55 例 OE 患者、12 例 AE 患者和 42 例 DE 患者的匹配对，这些患者在癌症家族史、产次和口服避孕药使用方面无差异。
使用以下主要抗体进行免疫组织化学检测：CD3+；CD4+；CD8+；PD-1；PD-L1。
描述 4 种不同的子宫内膜异位症相关疾病中 T 淋巴细胞浸润和 PD-1/PD-L1 表达的特征。
与所有其他子宫内膜异位症相关疾病（OE、AE 和 DE）相比，子宫内膜异位症相关卵巢癌病例显示出显著更高水平的 PD-1/PD-L1 表达（vs. OE vs. AE vs. DE）。此外，与 OE 病例相比，EAOC 病例中浸润 T 淋巴细胞的数量显著减少。最后，三分之一的 OE 病例表现出类似癌症的 PD-1/PD-L1 表达谱。
与良性子宫内膜异位症相关疾病相比，子宫内膜异位症相关卵巢癌的 PD-1/PD-L1 表达水平更高。这种表型在三分之一的临床良性病例中发现，提示它在癌变过程的早期就已经发展。
